| Composition | Voglibose 0.2mg Repaglinide 1mg |
|---|---|
| Dosage | TABLET |
| Packing Size | 10×10 |
| Packing | Strip |
VOGLICOP R 0.2/1 is a combination oral antidiabetic medication formulated with Voglibose (0.2 mg) and Repaglinide (1 mg). This dual-action therapy helps control postprandial blood glucose levels in patients with type 2 diabetes mellitus by targeting glucose absorption and insulin secretion.
The synergistic effect of these two agents provides effective glycemic control, helping to reduce the risk of diabetes-related complications and maintain metabolic balance.
Each tablet contains:
Voglibose 0.2 mg – An alpha-glucosidase inhibitor that slows carbohydrate digestion and absorption in the intestines, thereby reducing post-meal blood glucose spikes.
Repaglinide 1 mg – A meglitinide derivative that stimulates insulin secretion from pancreatic beta cells in response to elevated blood glucose levels.
(Excipients q.s., as per approved formulation.)
Tablet
Oral Antidiabetic / Blood Glucose Regulator
VOGLICOP R 0.2/1 Tablets are indicated for:
Type 2 Diabetes Mellitus in adults
Patients inadequately controlled with diet and exercise alone
Managing postprandial hyperglycemia
Combination therapy for improved glycemic control
Voglibose delays the digestion and absorption of carbohydrates in the small intestine, reducing postprandial glucose rise.
Repaglinide stimulates rapid, short-acting insulin release from the pancreas, especially after meals.
The combination provides better blood sugar control than either agent alone by targeting both insulin secretion and glucose absorption.
Recommended Dose: As prescribed by a physician, usually before meals.
Route: Oral
Duration: As per medical guidance, based on glycemic control and patient response.
Note: Regular monitoring of blood glucose levels is recommended during therapy.
Effective postprandial blood sugar control
Helps reduce fasting and post-meal glucose spikes
Dual action on glucose absorption and insulin secretion
Supports better long-term glycemic control
Can be combined with other antidiabetic therapies as per physician’s advice
VOGLICOP R 0.2/1 is generally well tolerated. Possible side effects include:
Mild hypoglycemia (especially with inadequate food intake)
Gastrointestinal disturbances such as bloating, diarrhea, or abdominal discomfort
Rare allergic reactions
Patients should report persistent side effects to their healthcare provider.
Use with caution in renal or hepatic impairment
Monitor blood glucose regularly to avoid hypoglycemia
Not recommended for type 1 diabetes mellitus or diabetic ketoacidosis
Consult your physician before use during pregnancy or lactation
Inform the doctor about other medications being taken
Store below 25°C, in a dry place away from direct sunlight. Keep out of reach of children.
Brand Name: VOGLICOP R 0.2/1
Composition: Voglibose 0.2 mg + Repaglinide 1 mg
Dosage Form: Tablet
Therapeutic Class: Oral Antidiabetic
Manufacturer: [Insert Company Name]
Packaging: [Example: 10×10 Tablets / Strip]
Dual-action therapy targeting both insulin secretion and carbohydrate absorption
Helps maintain stable blood glucose levels throughout the day
Effective for type 2 diabetes patients inadequately controlled on diet or monotherapy
Manufactured under strict GMP quality standards
VOGLICOP R 0.2/1 Tablets (Voglibose 0.2 mg + Repaglinide 1 mg) provide comprehensive postprandial glycemic control for patients with type 2 diabetes. By combining fast-acting insulin secretion with delayed carbohydrate absorption, it helps manage blood sugar spikes, improve overall glycemic control, and support a healthier, balanced lifestyle.
